Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Research & Development (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Research & Development readings, the most recent being $6.2 million for Q4 2023.

  • On a quarterly basis, Research & Development rose 43.52% to $6.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $23.8 million, a 6.81% decrease, with the full-year FY2025 number at $24.9 million, down 26.01% from a year prior.
  • Research & Development hit $6.2 million in Q4 2023 for Elicio Therapeutics, down from $7.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $14.4 million in Q2 2021 to a low of $4.3 million in Q4 2022.
  • Median Research & Development over the past 4 years was $7.0 million (2021), compared with a mean of $8.6 million.
  • Biggest five-year swings in Research & Development: soared 118.34% in 2021 and later crashed 65.43% in 2022.
  • Elicio Therapeutics' Research & Development stood at $11.1 million in 2020, then crashed by 39.74% to $6.7 million in 2021, then plummeted by 35.66% to $4.3 million in 2022, then surged by 43.52% to $6.2 million in 2023.
  • The last three reported values for Research & Development were $6.2 million (Q4 2023), $7.3 million (Q3 2023), and $4.9 million (Q2 2023) per Business Quant data.